Dr. Moslehi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
555 Mission Bay Blvd S
San Francisco, CA 94143Phone+1 415-353-3109Fax+1 415-353-2528
Summary
- I am a cardiologist and myocyte biologist. My clinical focus is cardio-oncology (the cardiovascular care of cancer patients and cancer survivors). My basic and translational NIH-funded laboratory addresses myocardial responses to various stresses including hypoxia, aging and toxins. Over the last several years, given my clinical interest in cardio-oncology, my laboratory focus has been in delineating the mechanistic underpinnings of cardiovascular toxicities from novel targeted cancer therapies. I believe because of the targeted nature of the toxicities, cardio-oncology can provide insights into novel signaling pathways that are relevant in human cardiovascular biology and pathology.
At University of California, San Francisco (UCSF), I am the William Grossman Distinguished Professor of Cardiology and Associate Professor in Residence and Founding Chief of a new section focused on Cardio-Oncology and Immunology. I work closely with cardiologists and oncologists, basic and translational researchers and clinicians locally, nationally and internationally. I have multiple collaborations with industry and regulatory bodies (including the US FDA). In 2019, I was named the first chair of the American Heart Association (AHA) cardio-oncology subcommittee. At Vanderbilt and UCSF, I established a Graduate Medical Education (GME) approved fellowship training the next generation of physician-scientists in the field of cardio-oncology. I am an elected member of American Society of Clinical Investigation (ASCI).
Education & Training
- Harvard Medical School/Dana-Farber Cancer InstitutePost-Doctoral Fellowship, Molecular Biology, , 2007 - 2014
- Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2004 - 2007
- Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004
- Uconn School Of MedicineClass of 2001
Certifications & Licensure
- CA State Medical License 2021 - 2025
- TN State Medical License 2014 - 2023
- AL State Medical License 2020 - 2020
- MA State Medical License 2004 - 2015
Clinical Trials
- Cardiac Fibrosis by CMR in Patients With Cancer Start of enrollment: 2013 Mar 01
- Detection of Cardiac Fibrosis in Patients With Lymphoma Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- 49 citationsHarnessing big data to characterize immune-related adverse events.Ying Jing, Jingwen Yang, Douglas B Johnson, Javid J Moslehi, Leng Han
Nature Reviews. Clinical Oncology. 2022-04-01 - 741 citations2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and On...Alexander R Lyon, Teresa López-Fernández, Liam S Couch, Riccardo Asteggiano, Marianne C Aznar
European Heart Journal. 2022-11-01 - 928 citationsMYOCARDITIS IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORSSyed S. Mahmood, Michael G. Fradley, Justine V. Cohen, Anju Nohria, Kerry L. Reynolds
Journal of the American College of Cardiology. 2018-04-24
Lectures
- Cancer Immunotherapies in Myocarditis2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- What Cancer and Cancer Therapeutics Can do to Your Blood Vessels: Biologic Mechanisms and Role for Precision Medicine2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
- Vasculo-Oncology 2019: An Emerging Field--Be a Part of It2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
- Join now to see all
Press Mentions
- Damar Hamlin’s Cardiac Arrest: What We Know and Don’t KnowJanuary 3rd, 2023
- Myocarditis in Cancer Patients Is Driven by Specific Immune CellsNovember 18th, 2022
- Immunotherapy-Related Myocarditis Linked to T Cells Targeting Cardiac-Specific AntigenNovember 17th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: